Document is current
Any future updates will be listed below
-
Authors
Nair, Nishanth Ulhas https://orcid.org/0000-0002-8832-0329
Greninger, Patricia https://orcid.org/0000-0001-9110-7695
Zhang, Xiaohu
Friedman, Adam A.
Amzallag, Arnaud
Cortez, Eliane
Sahu, Avinash Das
Lee, Joo Sang https://orcid.org/0000-0001-8564-0848
Dastur, Anahita
Egan, Regina K.
Murchie, Ellen
Ceribelli, Michele
Crowther, Giovanna S.
Beck, Erin
McClanaghan, Joseph
Klump-Thomas, Carleen https://orcid.org/0000-0002-6646-6132
Boisvert, Jessica L.
Damon, Leah J.
Wilson, Kelli M. https://orcid.org/0000-0003-2636-2766
Ho, Jeffrey
Tam, Angela
McKnight, Crystal
Michael, Sam
Itkin, Zina
Garnett, Mathew J. https://orcid.org/0000-0002-2618-4237
Engelman, Jeffrey A.
Haber, Daniel A. https://orcid.org/0000-0003-1378-6551
Thomas, Craig J. https://orcid.org/0000-0001-9386-9001
Ruppin, Eytan https://orcid.org/0000-0002-7862-3940
Benes, Cyril H. https://orcid.org/0000-0002-8751-9707
-
Funding
Funding for this research was provided by:
Wellcome Trust (102696)
- License Information
-
More Information
Article History
Received: 31 January 2023
Accepted: 14 June 2023
First Online: 28 June 2023
Competing interests
: E.R., is a non-paid scientific consultant and cofounder (divested) of Pangea Therapeutics (), which focuses on synthetic lethality based precision; he is also a co-founder of MedAware and Metabomed Ltd. C.H.B., is employee of Novartis and previously received research funding from Novartis. A.F., is an employee at Scorpion Therapeutics. A.D.S. provides consultancy to Lead Pharma, Checkmate Pharmaceuticals and C-Reveal Therapeutics. D.A.H., is cofounder of Tell-Bio and on the SAB of Rome Therapeutics. All other authors declare no conflict of interest.
